GlassScriptPhysician profile
Jaime Young
NPI 1780157651
$1,677.51
in general payments reported to CMS, 2019-2025
17 companies · $334 in 2025
The $334 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $258 · 2022: $163 · 2023: $437 · 2024: $486 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,256.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $499.95 | 2023-2025 | |
| Viiv Healthcare Company | $342.07 | 2021-2024 | Dovato |
| Napo Pharmaceuticals INC | $127.86 | 2023-2024 | Mytesi |
| Dexcom, INC. | $125.00 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Janssen Biotech, INC. | $105.09 | 2021-2022 | |
| Janssen Products, LP | $79.99 | 2022 | |
| Theratechnologies INC. | $79.23 | 2023-2025 | Egrifta, Trogarzo |
| Abbvie INC. | $66.04 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $59.86 | 2021-2023 | Dificid, Delstrigo, Pifeltro |
| Novo Nordisk INC | $47.21 | 2023-2024 | Ozempic |
| Hologic Sales and Service, LLC | $29.23 | 2024 | Aptima |
| Exact Sciences Corporation | $22.78 | 2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $22.76 | 2023 | Farxiga |
| Pfizer INC. | $22.17 | 2023 | |
| Astellas Pharma US INC | $19.66 | 2024 | Veozah |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $14.44 | 2025 | Dupixent |
| Currax Pharmaceuticals LLC | $14.17 | 2023 | Nexletol, Nexlizet, Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.